Sully.ai
-53%
est. 2Y upside i
AutonomousOS for healthcare organizations
Rank
#721
Sector
HealthTech
Est. Liquidity
~5Y
Data Quality
Data: MediumSully.ai presents a strong upside opportunity driven by its innovative AI solutions in a rapidly growing HealthTech market.
Last updated: March 10, 2026
Sully.ai leverages its proprietary, healthcare-specific AI models and deep EHR integrations to become a dominant player in healthcare administrative automation and medical scribing. Strategic partnerships, such as the global expansion with Speechmatics, and continued outperformance against tech giants in benchmarks drive rapid adoption, pushing revenue to over $100M by 2028 and justifying a valuation of $750M (5x current valuation) or more, representing a 400% upside.
Sully.ai maintains strong growth in its core segments, securing additional funding rounds (Series B/C) and expanding its customer base. It successfully navigates regulatory hurdles and fends off some competitive pressures, growing revenue to approximately $35-40M by 2028. This growth supports a valuation of around $260M (1.75x current valuation), offering a 75% upside for common shareholders.
Dominant incumbents like Google Health or Microsoft (Nuance) intensify their focus on healthcare AI, leveraging their vast resources and existing market access to commoditize Sully.ai's offerings. Regulatory complexities or slower-than-expected adoption hinder growth, leading to a down round or an acquisition at a significantly lower valuation, potentially around $30M. Given the $32M in liquidation preferences, common stock holders would see an 80% loss or more.
Preference Stack Risk
highFunding Intensity
21%Investors hold $32M in liquidation preferences. In an exit at or below $32M, common stock would receive nothing. At the current $150M valuation, common stock would see value after the initial $32M is returned to preferred shareholders.
Dilution Risk
highAs a Series A company, Sully.ai will likely require multiple future funding rounds (Series B, C, etc.) before a liquidity event, which will lead to significant dilution for early common stock holders.
Secondary Liquidity
noneThere is currently no active secondary market or tender offers expected for a Series A company of this stage.
Questions to Ask at the Interview
Strategic questions based on Sully.ai's data — designed to show you've done your homework.
- 1
“How does Sully.ai plan to maintain its performance edge and proprietary data advantage against the rapidly evolving general-purpose AI models from tech giants like Google and OpenAI, especially given their vast resources and potential to adapt their models for healthcare?”
- 2
“With a subscription model of $1,188 per physician annually, what is Sully.ai's strategy for scaling customer acquisition and expanding its market penetration beyond the current ~7% in a highly regulated and relationship-driven healthcare market?”
- 3
“Given the Series A funding and the current $150M valuation, what is the company's anticipated timeline for future funding rounds and potential liquidity events for employees, and how is the company managing potential dilution for common stock holders?”
Community
Valuation Sentiment
Our model estimates -53% upside. What do you think?
Anonymous. Do not share material non-public information.
Community Discussion
Comments are reviewed before they appear publicly.
Loading comments...
Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.